What Drugs Can Trigger Autoimmune Disease?

Dozens of widely prescribed medications can push the immune system into attacking the body’s own tissues, producing conditions that look and feel like classic autoimmune diseases. The list spans heart drugs, antibiotics, diabetes medications, acne treatments, cancer immunotherapies, and even some of the biologic drugs designed to treat autoimmune conditions themselves. In most cases, the resulting disease fades once the drug is stopped, but not always, and the delay between starting a medication and developing symptoms can stretch from weeks to years, making the connection easy to miss.

Drug-Induced Lupus, the Textbook Example

The best-studied form of drug-triggered autoimmunity is drug-induced lupus. It mimics systemic lupus erythematosus, with joint pain, fever, fatigue, and sometimes inflammation of the lining around the heart or lungs. The blood pressure drug hydralazine and the heart rhythm drug procainamide are the two most historically associated culprits, though other medications including isoniazid (a tuberculosis drug), methyldopa (another blood pressure drug), chlorpromazine (an antipsychotic), quinidine, and the antibiotic minocycline have also been linked to it.¹ Hydralazine-induced lupus was first described in 1953, and it develops in roughly 5 to 10 percent of people who take the drug.

A hallmark of drug-induced lupus is the appearance of anti-histone antibodies in the blood. These antibodies target histone proteins, which are the spools around which DNA wraps inside cells. The specific antibody pattern differs depending on the offending drug. In procainamide-induced lupus, patients tend to produce IgG antibodies that react strongly with complexes of histones bound to DNA, a pattern similar to what is seen in naturally occurring lupus. Hydralazine-induced lupus, by contrast, tends to produce IgM antibodies that react more with free histones than with histone-DNA complexes.² Researchers have concluded that these two drugs likely trigger autoimmunity through somewhat different pathways, even though the clinical results look similar.³

A newer dimension of drug-induced lupus involves a wider range of modern medications. Analysis of VigiBase, the World Health Organization’s global adverse-event reporting database, has expanded the list of drugs associated with lupus-like syndromes well beyond the classic handful, reflecting the growing number of drug classes in use.⁴

Skin Conditions Triggered by Medications

Drug-induced autoimmunity is not limited to the systemic lupus pattern. Several skin-specific autoimmune diseases can be set off by medications, and the drugs involved are sometimes surprising.

Proton pump inhibitors, the widely used acid-reflux drugs such as omeprazole and lansoprazole, have been linked to a form of lupus that primarily affects the skin called subacute cutaneous lupus erythematosus. A study identifying 24 cases found that the rash appeared on average about eight months after starting the medication, though it ranged from as little as one week to as long as three and a half years. After stopping the drug, the skin changes typically resolved within about three months. Most patients tested positive for anti-Ro/SSA antibodies, which are the autoantibodies more commonly associated with the skin-predominant form of lupus.⁵ A European study comparing drug-induced skin lupus with the naturally occurring form found that although the clinical appearance and blood-test results were largely identical, microscopic examination of skin biopsies did show some differences, making biopsy a potentially useful diagnostic tool when the cause is uncertain.⁶

Bullous pemphigoid, an autoimmune blistering disease that mainly affects older adults, has been linked to a class of diabetes drugs called gliptins (DPP-4 inhibitors). The association has been confirmed in multiple studies, with vildagliptin carrying the strongest signal among the drugs in the class.⁷ The exact mechanism remains unclear, though the enzyme these drugs inhibit plays a role in immune regulation, and interfering with it may tip the balance in susceptible individuals.⁸

The Paradox of Biologic Therapies

Among the more counterintuitive drug-triggered autoimmune reactions is “paradoxical psoriasis.” TNF-alpha inhibitors are powerful biologic drugs used specifically to treat autoimmune conditions like Crohn’s disease, rheumatoid arthritis, and psoriasis. Yet in a subset of patients, these same drugs provoke new psoriasis-like skin lesions, sometimes in people who never had psoriasis before.⁹ The phenomenon cannot be dismissed as rare; some studies estimate it occurs in more than 10 percent of patients receiving anti-TNF therapy.¹⁰

Although the lesions resemble ordinary psoriasis clinically, research suggests they involve somewhat different immune pathways. One working theory is that blocking TNF-alpha tips the balance toward other inflammatory signals, particularly interferon-alpha, which then drives a distinct type of skin inflammation.¹¹ For clinicians, the treatment dilemma is obvious: the drug treating one autoimmune condition is creating another. The usual approach is to switch to a biologic in a different class, which often resolves the paradoxical lesions.

Autoimmune Liver Injury

Drug-induced autoimmune hepatitis is an increasingly recognized problem. It looks clinically similar to ordinary autoimmune hepatitis, with elevated liver enzymes, autoantibodies in the blood, and liver inflammation on biopsy. The two drugs with the strongest documented link are minocycline, an antibiotic prescribed heavily for acne, and nitrofurantoin, a urinary tract infection antibiotic.¹² The list extends to anti-TNF biologic agents like infliximab, the anti-inflammatory drug diclofenac, and statins. In fact, autoimmune features show up in a substantial fraction of statin-related liver injury cases, with estimates ranging from roughly 9 to 27 percent.¹³

A pharmacovigilance study using the FDA’s adverse event reporting system applied multiple statistical methods to flag drugs significantly associated with autoimmune hepatitis reports, helping researchers track which newer medications deserve closer monitoring and how long after starting a drug the liver problems tend to emerge.¹⁴ The overlap between drug-induced liver injury and genuine autoimmune hepatitis makes diagnosis tricky, which matters because the treatment decisions are different. Hydralazine and methyldopa, already mentioned for lupus, have also been implicated in liver injury with autoimmune features, underscoring how a single drug can provoke autoimmune trouble in multiple organs.¹⁵

Blood Vessels and Blood Cells

Some drugs trigger autoimmune attacks on blood vessels, a condition called ANCA-associated vasculitis. ANCA stands for antineutrophil cytoplasmic antibodies, which are autoantibodies that target proteins inside white blood cells called neutrophils. When present, these antibodies can cause widespread inflammation in small blood vessels, potentially damaging the kidneys, lungs, and skin. The main drug culprits include hydralazine, propylthiouracil (a thyroid medication), minocycline, and levamisole, a veterinary deworming agent that has been found as a contaminant in cocaine.¹⁶¹⁷

Drugs can also turn the immune system against red blood cells, causing drug-induced immune hemolytic anemia. Here the antibiotics are the main offenders: cefotetan, ceftriaxone, and piperacillin are the most frequently involved at present. The mechanism often involves the drug binding to proteins on the surface of red blood cells. The immune system then produces antibodies against the drug-coated cells, and the spleen filters those cells out and destroys them, leading to anemia.¹⁸

Cancer Immunotherapy and the Immune Brake Problem

Checkpoint inhibitor immunotherapies, which have transformed cancer treatment, work by releasing the brakes on the immune system so it can attack tumors more aggressively. One major brake is the PD-1 pathway, which normally helps maintain immune tolerance in peripheral tissues.¹⁹ Releasing that brake can produce dramatic responses against cancer, but it can also unleash the immune system against healthy organs. The resulting autoimmune-like side effects, called immune-related adverse events, can affect almost any organ: the thyroid, the pituitary gland, the liver, the lungs, the colon, the skin, the joints, and the nervous system. These side effects can appear weeks to months into treatment and sometimes persist long after the drug is stopped, distinguishing them from many other drug-induced autoimmune conditions.

Thyroid dysfunction is one of the more common immune-related adverse events with checkpoint inhibitors, and it is worth noting that thyroid autoimmunity can also be provoked by other drugs entirely unrelated to cancer. Lithium, used for bipolar disorder, and amiodarone, a heart rhythm drug, both decrease thyroid hormone production in some patients and can trigger thyroid autoimmunity. Interferon-alpha, once widely used for hepatitis C, is known to provoke thyroid autoimmune reactions through a cytokine-mediated pathway.

How Drugs Actually Trigger Autoimmunity

There is no single mechanism by which medications provoke autoimmune disease. Several distinct pathways have been identified, and in many cases a given drug may engage more than one.

The oldest explanation is the hapten model. Most drugs are too small on their own to attract the attention of the immune system. But if a drug or one of its breakdown products bonds tightly to a protein in the body, the combination can look foreign enough to trigger an immune response, much as a tiny dye stain changes the appearance of a shirt. This is the model that best explains penicillin-related immune reactions and drug-induced hemolytic anemia. A newer concept, called the pharmacological interaction model, proposes that some drugs can slot directly into immune receptors without forming a permanent bond, essentially tricking immune cells into activating as though they have encountered a foreign invader.²⁰²¹

For drug-induced lupus specifically, an epigenetic mechanism appears central. Both hydralazine and procainamide inhibit DNA methylation in certain immune cells. Methylation is a chemical tag that normally keeps some genes switched off. When the tag is removed, genes that should be silent become active, and the affected immune cells begin behaving in self-reactive ways, attacking the body’s own tissues.²² Animal studies have confirmed this: transferring immune cells treated with methylation-inhibiting drugs into healthy mice produces a lupus-like illness.²³ Strikingly, the same type of altered immune cells are found in people with naturally occurring lupus, suggesting that drug-induced and spontaneous lupus may share more biology than previously appreciated.

A third mechanism involves neutrophil extracellular traps, or NETs. Neutrophils are frontline immune cells that sometimes sacrifice themselves by expelling webs of DNA and proteins to catch invaders. When this process goes into overdrive, the released DNA and histones can become targets for autoantibodies. Hydralazine and procainamide have both been shown to significantly increase NET formation in lab experiments, though they do so through different cellular triggers: procainamide activates a specific receptor on neutrophils, while hydralazine works by changing calcium release inside the cells.²⁴ Levamisole, the cocaine adulterant linked to vasculitis, also ramps up NET formation, and patients using levamisole-adulterated cocaine develop autoantibodies against NET components.²⁵

Why Some People Are More Vulnerable

Not everyone who takes hydralazine gets lupus, and not everyone on a checkpoint inhibitor develops thyroid problems. Genetic variation plays a clear role. One well-characterized example involves the enzyme N-acetyltransferase 2 (NAT2), which metabolizes hydralazine. People who carry genetic variants that make this enzyme work slowly end up with higher drug levels in their blood for longer. A clinical pharmacogenetics guideline now recommends considering NAT2 genotype when prescribing hydralazine, because slow metabolizers face an elevated risk of drug-induced lupus compared with people who clear the drug more quickly.²⁶

Beyond specific metabolizing enzymes, variations in immune-system genes likely influence susceptibility across many drug classes. These are harder to pin down because autoimmune reactions remain uncommon events, making it difficult to assemble study groups large enough to identify all the relevant genetic variants. Researchers also suspect that the gut microbiome plays a modifying role. Medications reshape the mix of gut bacteria, and those shifts can have downstream effects on immune regulation. Some bacterial species help maintain immune tolerance, and losing them to antibiotic exposure or other drug effects may lower the threshold for autoimmune activation.²⁷ Separately, certain gut bacteria can increase intestinal permeability, potentially allowing bacterial products into the bloodstream where they can stimulate a misdirected immune response.²⁸

How Drug-Induced Autoimmunity Is Recognized and Managed

Diagnosing drug-induced autoimmune disease is often a process of exclusion. The symptoms and lab findings frequently overlap with those of naturally occurring autoimmune conditions, so clinicians need a high index of suspicion and a careful medication timeline. The key diagnostic clue is temporal: symptoms began after starting the drug, and they improve after stopping it. Because resolution of symptoms generally follows cessation of the offending drug, early recognition is important for both treatment and prognosis.²⁹

In drug-induced lupus, the presence of anti-histone antibodies with the absence of anti-double-stranded DNA antibodies (which are more characteristic of spontaneous lupus) can be a useful distinguishing marker, though it is not foolproof. For drug-induced autoimmune hepatitis, the challenge is especially acute because if clinicians mistake it for ordinary autoimmune hepatitis, the patient may end up on long-term immunosuppressive therapy that they do not actually need. In many cases, simply stopping the offending medication is sufficient, though some patients require a short course of corticosteroids to control symptoms, and a small number develop persistent autoimmune disease that continues even after the drug is gone.

Levamisole-Adulterated Cocaine as an Unusual Case Study

One of the more striking real-world examples of drug-triggered autoimmunity involves levamisole, a veterinary deworming agent that has been widely used as an adulterant in cocaine. People using levamisole-contaminated cocaine have developed severe autoimmune vasculitis, often presenting with painful purplish skin lesions on the ears, nose, and cheeks, along with dangerously low white blood cell counts. Levamisole triggers excessive NET formation through a specific receptor pathway on neutrophils, and patients with active exposure develop autoantibodies against the components released in those NETs.²⁵ The condition can be severe and even fatal, and it illustrates how drug-induced autoimmunity is not limited to prescription medications. Environmental and recreational exposures matter too, and any substance that interacts with the immune system is a potential trigger in the right genetic background.

Drugs That Can Trigger Autoimmunity at a Glance

Because the list of implicated drugs spans so many therapeutic categories, a rough grouping can help orient anyone trying to understand the landscape:

• Heart and blood pressure drugs: hydralazine, procainamide, quinidine, methyldopa
• Antibiotics: minocycline, nitrofurantoin, isoniazid, cefotetan, ceftriaxone, piperacillin
• Diabetes drugs: DPP-4 inhibitors (gliptins), particularly vildagliptin
• Acid reflux drugs: proton pump inhibitors (omeprazole, lansoprazole, others)
• Psychiatric drugs: lithium, chlorpromazine
• Biologic agents: TNF-alpha inhibitors (infliximab, etanercept, adalimumab), checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab)
• Thyroid drugs: propylthiouracil
• Cholesterol drugs: statins (atorvastatin, rosuvastatin)
• Other: amiodarone, interferon-alpha, levamisole (as a cocaine adulterant)

The conditions these drugs produce range from lupus-like syndromes and skin eruptions to liver inflammation, blood vessel damage, blistering skin diseases, anemia, and thyroid dysfunction. Most are reversible with drug withdrawal, but the time to recovery varies widely, and some individuals require immunosuppressive treatment to get the immune response back under control. If you develop new symptoms that feel autoimmune in character, especially joint pain, unexplained rashes, unusual fatigue, or dark urine while on any long-term medication, bringing up the medication timeline with your doctor is one of the most useful things you can do.